- Home
- CRVS vs LPAA Comparison
CRVS vs LPAA Comparison
Compare CRVS & LPAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- LPAA
- Stock Information
- Founded
- CRVS 2014
- LPAA 2024
- Country
- CRVS United States
- LPAA United States
- Employees
- CRVS N/A
- LPAA N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- LPAA
- Sector
- CRVS Health Care
- LPAA
- Exchange
- CRVS Nasdaq
- LPAA Nasdaq
- Market Cap
- CRVS 335.1M
- LPAA 290.4M
- IPO Year
- CRVS 2016
- LPAA 2024
- Fundamental
- Price
- CRVS $4.19
- LPAA $10.14
- Analyst Decision
- CRVS Strong Buy
- LPAA
- Analyst Count
- CRVS 5
- LPAA 0
- Target Price
- CRVS $12.38
- LPAA N/A
- AVG Volume (30 Days)
- CRVS 419.4K
- LPAA 38.2K
- Earning Date
- CRVS 03-18-2025
- LPAA 01-01-0001
- Dividend Yield
- CRVS N/A
- LPAA N/A
- EPS Growth
- CRVS N/A
- LPAA N/A
- EPS
- CRVS N/A
- LPAA N/A
- Revenue
- CRVS N/A
- LPAA N/A
- Revenue This Year
- CRVS N/A
- LPAA N/A
- Revenue Next Year
- CRVS N/A
- LPAA N/A
- P/E Ratio
- CRVS N/A
- LPAA N/A
- Revenue Growth
- CRVS N/A
- LPAA N/A
- 52 Week Low
- CRVS $1.30
- LPAA $9.66
- 52 Week High
- CRVS $10.00
- LPAA $10.14
- Technical
- Relative Strength Index (RSI)
- CRVS 28.71
- LPAA N/A
- Support Level
- CRVS $4.60
- LPAA N/A
- Resistance Level
- CRVS $5.19
- LPAA N/A
- Average True Range (ATR)
- CRVS 0.30
- LPAA 0.00
- MACD
- CRVS -0.06
- LPAA 0.00
- Stochastic Oscillator
- CRVS 2.01
- LPAA 0.00
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About LPAA Launch One Acquisition Corp. Class A Ordinary shares
Launch One Acquisition Corp is a blank check company.